Zymeworks will participate in upcoming investor conferences this month, engaging with members of the investment community on our strategy and portfolio.
This week our schedule includes:
- November 11 – @Stifel Healthcare Conference
- November 12 – @Truist BioPharma Symposium
in the @Jefferies London Healthcare Conference next week on November 17.
Visit our website for event details: lnkd.in/gzFaAHj6
This week our schedule includes:
- November 11 – @Stifel Healthcare Conference
- November 12 – @Truist BioPharma Symposium
in the @Jefferies London Healthcare Conference next week on November 17.
Visit our website for event details: lnkd.in/gzFaAHj6
0
0
0
39
Tomorrow at the Society for Immunotherapy of Cancer Annual Meeting, our team will present new preclinical data on a novel approach to targeted IL-7 delivery.
The approach incorporates IL-7 into a multispecific antibody designed to deliver the cytokine to tumor-specific T cells, gies intended to limit activity on bystander T cells.
Presentation: Engineering targeted IL-7 delivery to enhance anti-tumor T cell fitness and persistence
Abstract: 810
Date: Saturday, November 7
Location: PCC-North Building, Lower Level, Exhibition Halls 4–5–6
Learn more: zymeworks.com/zymeworks-pres…
#SITC2026
The approach incorporates IL-7 into a multispecific antibody designed to deliver the cytokine to tumor-specific T cells, gies intended to limit activity on bystander T cells.
Presentation: Engineering targeted IL-7 delivery to enhance anti-tumor T cell fitness and persistence
Abstract: 810
Date: Saturday, November 7
Location: PCC-North Building, Lower Level, Exhibition Halls 4–5–6
Learn more: zymeworks.com/zymeworks-pres…
#SITC2026
0
0
3
70
Zymeworks will be presenting at the 2026 American Society of Hematology Annual Meeting, sharing preclinical data on ZW1953, a new CD3 multispecific T cell engager designed to target FLT3, CLEC12A, and CD33 with conditional CD28 co-stimulation for AML.
Learn more: zymeworks.com/zymeworks-to-p…
#ASH26
Learn more: zymeworks.com/zymeworks-to-p…
#ASH26
0
0
2
86
Today at #ESMO26 in Madrid, we shared new Phase 1 data on our investigational FRα-targeting antibody-drug conjugate in heavily pretreated patients with platinum-resistant ovarian cancer.
The results reinforce our confidence in the potential of this approach to help expand atients with ovarian cancer.
Read the key data highlights here: ir.zymeworks.com/news-releases/…
#OvarianCancer #ADC
The results reinforce our confidence in the potential of this approach to help expand atients with ovarian cancer.
Read the key data highlights here: ir.zymeworks.com/news-releases/…
#OvarianCancer #ADC
1
0
5
153
Zymeworks has entered into an exclusive global license and collaboration agreement with @Roche for ZW209, a DLL3-targeting trispecific T cell engager.
Under the agreement, Zymeworks is eligible to receive a $55 million upfront payment, a $40 million payment upon initiation of up to $718 million in additional development, commercial and sales-based milestones, plus tiered royalties on future global net sales.
Zymeworks will conduct the Phase 1a monotherapy trial in collaboration with Roche, which will fund the trial and lead subsequent global development and commercialization.
The agreement reflects Zymeworks’ strategy of advancing innovative programs through its R&D engine and partnering selected assets to share development risk while retaining meaningful participation in future success.
Read the full announcement: lnkd.in/garA3Vi7
Zymeworks management will host a conference call on October 27 at 8:30 am ET.
#Oncology #RocheInnovation #pRED
Under the agreement, Zymeworks is eligible to receive a $55 million upfront payment, a $40 million payment upon initiation of up to $718 million in additional development, commercial and sales-based milestones, plus tiered royalties on future global net sales.
Zymeworks will conduct the Phase 1a monotherapy trial in collaboration with Roche, which will fund the trial and lead subsequent global development and commercialization.
The agreement reflects Zymeworks’ strategy of advancing innovative programs through its R&D engine and partnering selected assets to share development risk while retaining meaningful participation in future success.
Read the full announcement: lnkd.in/garA3Vi7
Zymeworks management will host a conference call on October 27 at 8:30 am ET.
#Oncology #RocheInnovation #pRED
0
2
5
259
We’re pleased to welcome Suzanne Monahan to Zymeworks as Senior Vice President, Commercial and General Manager, Theravance Biopharma.
Suzanne brings more than 20 years of commercial leadership experience across the pharmaceutical and medical device industries, with expertise in t access, strategic partnerships and respiratory markets.
In her new role, Suzanne will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of COPD. Read today's announcement: ir.zymeworks.com/news-releases/…
Suzanne brings more than 20 years of commercial leadership experience across the pharmaceutical and medical device industries, with expertise in t access, strategic partnerships and respiratory markets.
In her new role, Suzanne will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of COPD. Read today's announcement: ir.zymeworks.com/news-releases/…
0
0
2
153
Zymeworks will report its third quarter 2026 financial results on November 9, and participate in several investor conferences throughout November, including the Wolfe Research, Stifel, Truist Securities, and Jefferies Healthcare Conferences.
We look forward to engaging with the d sharing updates on our business and strategic priorities.
Read today’s announcement: ir.zymeworks.com/news-releases/…
We look forward to engaging with the d sharing updates on our business and strategic priorities.
Read today’s announcement: ir.zymeworks.com/news-releases/…
0
0
2
109
Giving back to the communities where we live and work is an important part of who we are at Zymeworks.
This week, employees across our hubs in Vancouver, Bellevue, New York City, Dublin, and Singapore came together for our annual all-staff giving-back event. Through hands-on y initiatives, we helped bring support and a little joy to more than 1,000 children receiving care in hospitals, as well as their families and caregivers.
We’re proud of what we accomplished together and grateful to everyone who gave their time and energy to make the day such a success.
This week, employees across our hubs in Vancouver, Bellevue, New York City, Dublin, and Singapore came together for our annual all-staff giving-back event. Through hands-on y initiatives, we helped bring support and a little joy to more than 1,000 children receiving care in hospitals, as well as their families and caregivers.
We’re proud of what we accomplished together and grateful to everyone who gave their time and energy to make the day such a success.
0
0
1
82
We’re heading into a busy fall conference season, with Zymeworks researchers presenting new clinical and preclinical data across multiple medical conferences.
At #ESMO26 on October 24, we’ll share new clinical results from our Phase 1 randomized dose optimization study of ZW191 atients with platinum-resistant ovarian cancer.
At #SITC26, we’ll present new preclinical data on a novel approach designed to target IL-7 to tumor-specific T cells.
At #PEGSEurope, we’ll showcase work across our next-generation multispecific programs and cytokine engineering.
Learn more here: lnkd.in/g8iDK7bX
At #ESMO26 on October 24, we’ll share new clinical results from our Phase 1 randomized dose optimization study of ZW191 atients with platinum-resistant ovarian cancer.
At #SITC26, we’ll present new preclinical data on a novel approach designed to target IL-7 to tumor-specific T cells.
At #PEGSEurope, we’ll showcase work across our next-generation multispecific programs and cytokine engineering.
Learn more here: lnkd.in/g8iDK7bX
1
0
2
159
Today, on the National Day for Truth and Reconciliation and Orange Shirt Day, we pause to remember the children who never came home and honour Survivors, their families and communities.
We recognize that reconciliation is an ongoing journey, and an opportunity to learn, reflect forward together.
We encourage everyone to take time to learn more about the history and significance of this day through resources from the National Centre for Truth and Reconciliation, today and throughout the year.
Learn more: nctr.ca
#NationalDayforTruthandReconciliation #OrangeShirtDay
We recognize that reconciliation is an ongoing journey, and an opportunity to learn, reflect forward together.
We encourage everyone to take time to learn more about the history and significance of this day through resources from the National Centre for Truth and Reconciliation, today and throughout the year.
Learn more: nctr.ca
#NationalDayforTruthandReconciliation #OrangeShirtDay
0
1
1
77
As Ovarian Cancer Awareness Month comes to a close, the need for awareness and support continues on.
For patients, caregivers and loved ones navigating a gynecologic cancer diagnosis, finding the right information and support can make a meaningful difference. Resources are everything from managing a diagnosis and finding support to navigating financial assistance and other challenges along the way.
Explore resources for patients and caregivers from the Ovarian Cancer Research Alliance: ocrahope.org/resources-supp…
#OvarianCancer #CancerAwareness #Oncology
For patients, caregivers and loved ones navigating a gynecologic cancer diagnosis, finding the right information and support can make a meaningful difference. Resources are everything from managing a diagnosis and finding support to navigating financial assistance and other challenges along the way.
Explore resources for patients and caregivers from the Ovarian Cancer Research Alliance: ocrahope.org/resources-supp…
#OvarianCancer #CancerAwareness #Oncology
0
0
1
69
We’ve completed the acquisition of Theravance Biopharma, advancing our strategy to build a productive R&D company with a growing portfolio of revenue-generating assets and diversified, durable cash flows.
We’re also pleased to welcome Stuart Knight as EVP & CIO and Jesse Fecker, Ph.D., Jl Property.
Read the full announcement: ir.zymeworks.com/news-releases/…
Join our conference call today at 8:30 am ET: edge.media-server.com/mmc/p/midqpich/
We’re also pleased to welcome Stuart Knight as EVP & CIO and Jesse Fecker, Ph.D., Jl Property.
Read the full announcement: ir.zymeworks.com/news-releases/…
Join our conference call today at 8:30 am ET: edge.media-server.com/mmc/p/midqpich/
0
1
1
133
Our Zymeworks team came together at Stanley Park this past weekend to run, walk and support @TerryFoxCanada's vision of a world without cancer. The Terry Fox Run continues to bring people together across Canada to raise funds for cancer research and carry forward Terry’s uge congratulations to our team on an amazing fundraising effort, and thank you to everyone who ran, walked, donated, fundraised or cheered us on.
Well done, Team Zymeworks!
#TerryFoxRun #CancerResearch
Well done, Team Zymeworks!
#TerryFoxRun #CancerResearch
0
0
5
92
Today, we announced the completion of our acquisition of Theravance Biopharma.
With the transaction now complete, Theravance Biopharma is officially part of Zymeworks, marking an important step in our strategy to build a diversified, revenue-generating biotechnology company D with growing commercial and royalty-based cash flows.
We’ll host a conference call for investors and the general public on Monday, September 28 at 8:30 am ET to discuss the final transaction details.
Learn more and access the webcast: ir.zymeworks.com/news-releases/…
With the transaction now complete, Theravance Biopharma is officially part of Zymeworks, marking an important step in our strategy to build a diversified, revenue-generating biotechnology company D with growing commercial and royalty-based cash flows.
We’ll host a conference call for investors and the general public on Monday, September 28 at 8:30 am ET to discuss the final transaction details.
Learn more and access the webcast: ir.zymeworks.com/news-releases/…
0
0
5
112
We’re pleased to share that our FRα-targeting antibody-drug conjugate (#ADC) has been selected for a Rapid Oral Presentation at the 2026 @myESMO Congress in Madrid.
The presentation will feature new clinical results from our Phase 1 randomized dose optimization study in heavily h platinum-resistant ovarian cancer (PROC).
Title: Randomized dose optimization of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer
Date/Time: Saturday, October 24 at 8:30–10:00 am CET
View this year's program: cslide.ctimeetingtech.com/esmo2026/atten…
We look forward to sharing these findings with the oncology community at #ESMO26!
#OvarianCancer #CancerResearch
The presentation will feature new clinical results from our Phase 1 randomized dose optimization study in heavily h platinum-resistant ovarian cancer (PROC).
Title: Randomized dose optimization of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer
Date/Time: Saturday, October 24 at 8:30–10:00 am CET
View this year's program: cslide.ctimeetingtech.com/esmo2026/atten…
We look forward to sharing these findings with the oncology community at #ESMO26!
#OvarianCancer #CancerResearch
0
0
5
397
September is Ovarian Awareness Month — an opportunity to recognize the patients and families affected by these cancers and highlight the importance of continued research and innovation.
We’re proud to share a recently published study from our scientists exploring the preclinical eceptor alpha (FRα)-targeting antibody-drug conjugate. The research demonstrated promising anti-tumor activity across multiple tumor models, including ovarian and endometrial cancers, and provided insights into the differentiated properties of the antibody and payload.
Read the publication: lnkd.in/giA5kXAV
#OvarianCancer #ADC #CancerResearch
We’re proud to share a recently published study from our scientists exploring the preclinical eceptor alpha (FRα)-targeting antibody-drug conjugate. The research demonstrated promising anti-tumor activity across multiple tumor models, including ovarian and endometrial cancers, and provided insights into the differentiated properties of the antibody and payload.
Read the publication: lnkd.in/giA5kXAV
#OvarianCancer #ADC #CancerResearch
0
0
1
74
We’re pleased to share that Bijal Desai, SVP, Finance at Zymeworks, will participate in a panel discussion at Informa’s Life Sciences Product Launch Summit next week.
Bijal will join industry leaders for “Optimizing Gross-to-Net (GTN) and Financial Planning for Launch Success,” inancial planning in supporting successful product launches.
Tuesday, September 22
10:45–11:15 am ET
Learn more about the event: informaconnect.com/product-launch/
#LifeSciences #Biotech #Finance
Bijal will join industry leaders for “Optimizing Gross-to-Net (GTN) and Financial Planning for Launch Success,” inancial planning in supporting successful product launches.
Tuesday, September 22
10:45–11:15 am ET
Learn more about the event: informaconnect.com/product-launch/
#LifeSciences #Biotech #Finance
0
0
0
66
This week Zymeworks’ management team will participate in two healthcare investor conferences in New York:
Morgan Stanley Healthcare Conference — September 14
Fireside chat at 4:50 pm ET
H.C. Wainwright Annual Global Investment Conference — September 15
Fireside chat at 3:30 pm /t.co/3xGvde09O9
Morgan Stanley Healthcare Conference — September 14
Fireside chat at 4:50 pm ET
H.C. Wainwright Annual Global Investment Conference — September 15
Fireside chat at 3:30 pm /t.co/3xGvde09O9
0
0
0
77
Zymeworks’ management team will participate in two healthcare investor conferences this week:
Wells Fargo Healthcare Conference — September 8 in Boston, MA
Fireside chat at 3:45 pm ET
Citi’s Biopharma Back to School Summit — September 9 in New York, NY
Fireside chat at 3:40 pm /t.co/MwvRXiKRHu
Wells Fargo Healthcare Conference — September 8 in Boston, MA
Fireside chat at 3:45 pm ET
Citi’s Biopharma Back to School Summit — September 9 in New York, NY
Fireside chat at 3:40 pm /t.co/MwvRXiKRHu
0
0
0
91
As we recognize Ovarian Awareness Month, we’re highlighting our ongoing work to explore new approaches for patients with difficult-to-treat gynecological cancers.
In June, we shared new clinical findings from the Phase 1 study of our folate receptor alpha (FRα)-targeting at the ESMO Gynaecological Cancers Congress. Among response-evaluable patients with platinum-resistant ovarian cancer, the investigational therapy demonstrated anti-tumor activity across both FRα-positive and FRα-negative tumors, reinforcing the potential of this approach.
Zymeworks is currently evaluating strategic partnering opportunities to support the continued development of this program and maximize its long-term potential.
Learn more about the clinical findings: lnkd.in/e_iKFMyv
#OvarianCancerAwarenessMonth #OvarianCancer #GynecologicCancers #ADC #CancerResearch
In June, we shared new clinical findings from the Phase 1 study of our folate receptor alpha (FRα)-targeting at the ESMO Gynaecological Cancers Congress. Among response-evaluable patients with platinum-resistant ovarian cancer, the investigational therapy demonstrated anti-tumor activity across both FRα-positive and FRα-negative tumors, reinforcing the potential of this approach.
Zymeworks is currently evaluating strategic partnering opportunities to support the continued development of this program and maximize its long-term potential.
Learn more about the clinical findings: lnkd.in/e_iKFMyv
#OvarianCancerAwarenessMonth #OvarianCancer #GynecologicCancers #ADC #CancerResearch
0
0
2
94